|
11.
|
|
6 p, 377.9 KB |
Clinical and genetic differences between pustular psoriasis subtypes
/
Twelves, Sophie (King's College London) ;
Mostafa, Alshimaa (Beni Suef University) ;
Dand, Nick (King's College London) ;
Burri, Elias (University Hospital Zurich (Suïssa)) ;
Farkas, K. (University of Szeged) ;
Wilson, Rosemary (King's College London) ;
Cooper, Hywel L. (Portsmouth Hospitals Trust) ;
Irvine, Alan D. (Trinity College Dublin) ;
Oon, Hazel H. (National Skin Centre) ;
Kingo, Külli (Tartu University Hospital (Tartu, Estònia)) ;
Köks, Sulev (University of Tartu) ;
Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Reynolds, Nick (Newcastle Hospitals NHS Foundation Trust) ;
Tan, Euegene Sern-Ting (National Skin Centre) ;
Tanew, Adrian (Medical University of Vienna) ;
Torz, Kaspar (Campus Kiel) ;
Trattner, Hannes (Medical University of Vienna) ;
Valentine, Mark (University of Washington School of Medicine) ;
Wahie, Shyamal (University Hospital of North Durham and Darlington Memorial Hospital) ;
Warren, Richard B. (University of Manchester and the Academic Health Science Centre) ;
Wright, Andrew (St University of Bradford) ;
Bata-Csörgő, Zsuzsa (University of Szeged) ;
Szell, Marta (University of Szeged) ;
Griffiths, Christopher E.M. (University of Manchester and the Academic Health Science Centre) ;
Burden, A.David (University of Glasgow) ;
Choon, Siew-Eng (Monash University Malaysia) ;
Smith, Catherine H. (King's College London) ;
Barker, Jonathan N. (King's College London) ;
Navarini, Alexander A. (University Hospital Zurich (Suïssa)) ;
Capon, Francesca (King's College London) ;
Universitat Autònoma de Barcelona
The term pustular psoriasis indicates a group of severe skin disorders characterized by eruptions of neutrophil-filled pustules. The disease, which often manifests with concurrent psoriasis vulgaris, can have an acute systemic (generalized pustular psoriasis [GPP]) or chronic localized (palmoplantar pustulosis [PPP] and acrodermatitis continua of Hallopeau [ACH]) presentation. [...]
2019 -  10.1016/j.jaci.2018.06.038
The Journal of Allergy and Clinical Immunology, Vol. 143 Núm. 3 (march 2019) , p. 1021-1026
|
|
|
12.
|
|
18 p, 948.8 KB |
Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain : A Systematic Review
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Fernández-Freire, Lourdes Rodríguez (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Burgos-Pol, Ramón (Pharmacoeconomics and Outcomes Research Iberia (PORIB)) ;
Gomez, Ismael (Pfizer S.L.U.) ;
Peral, Carmen (Pfizer S.L.U.) ;
Gomez, Susana (Pfizer S.L.U.) ;
Rebollo Laserna, Francisco José (Pfizer S.L.U.) ;
Universitat Autònoma de Barcelona
Etanercept (ETN), a highly effective biological agent for the treatment of psoriasis (PSO) and psoriatic arthritis (PsA), is widely used in Spain. However, evidence of its economic impact is limited, indicating the need for a systematic review of the economic assessments conducted on the use of ETN in the treatment of both PSO and PsA in Spain. [...]
2019 - 10.1007/s13555-019-0301-6
Dermatology and Therapy, Vol. 9 Núm. 3 (january 2019) , p. 479-496
|
|
|
13.
|
|
7 p, 1.3 MB |
Absolute and relative psoriasis area and severity indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis : An integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Dossenbach, Martin (Eli Lilly and Company) ;
Berggren, Lovisa (Lilly Deutschland GmbH) ;
Ljungberg, Anders (Eli Lilly and Company) ;
Zachariae, Claus (University of Copenhagen) ;
Universitat Autònoma de Barcelona
Treatment goals defined by the absolute Psoriasis Area and Severity Index (PASI) scores offer certain advantages in the clinical setting. In order to investigate potential treatment targets, this study evaluated absolute PASI outcomes relative to other measures of response using data from two randomized clinical trials of patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept, or placebo (n=2,567). [...]
2019 - 10.2340/00015555-3245
Acta dermato-venereologica, Vol. 99 Núm. 11 (october 2019) , p. 971-977
|
|
|
14.
|
|
9 p, 1.1 MB |
The biological basis of disease recurrence in psoriasis : a historical perspective and current models
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Costanzo, Antonio (Humanitas University) ;
Muñoz-Elías, Ernesto J. (Janssen Research & Development) ;
Jazra, Maria (Medical Affairs) ;
Wegner, Sven (Janssen-Cilag GmbH) ;
Paul, Carle (Hôpital Larrey) ;
Conrad, Curdin (University Hospital CHUV) ;
Universitat Autònoma de Barcelona
A key challenge in psoriasis therapy is the tendency for lesions to recur in previously affected anatomical locations after treatment discontinuation following lesion resolution. Available evidence supports the concept of a localized immunological 'memory' that persists in resolved skin after complete disappearance of visible inflammation, as well as the role of a specific subpopulation of T cells characterized by the dermotropic CCR4 phenotype and forming a local memory. [...]
2022 - 10.1111/bjd.20963
British journal of dermatology, Vol. 186 Núm. 5 (may 2022) , p. 773-781
|
|
|
15.
|
|
9 p, 227.8 KB |
Prevalence of most common skin diseases in Europe : a population-based study
/
Richard, M.A. (University Hospital Timone) ;
Paul, C. (Université de Toulouse et CHU) ;
Nijsten, T. (Erasmus MC) ;
Gisondi, Paolo (University of Verona) ;
Salavastru, C. (Colentina Clinical Hospital) ;
Taieb, C. (EMMA) ;
Trakatelli, M. (Papageorgiou Hospital) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Stratigos, A. (National and Kapodistrian University of Athens) ;
Universitat Autònoma de Barcelona
The assessment of the prevalence of diseases is of primary importance in planning health policies. No complete data on the prevalence of skin diseases across European countries are available. Objective: To estimate the prevalence of the most frequent skin conditions or diseases in 27 European countries (24 EU countries, plus Norway, Switzerland, and the United Kingdom). [...]
2022 - 10.1111/jdv.18050
Journal of the European Academy of Dermatology and Venereology, Vol. 36 Núm. 7 (july 2022) , p. 1088-1096
|
|
|
16.
|
|
9 p, 1013.2 KB |
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis : a post hoc pooled analysis of AMAGINE-2 and -3
/
Reich, Kristian (University Medical Center Hamburg-Eppendorf) ;
Iversen, L. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Lambert, Jo (Ghent University) ;
Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ;
Kaplan Saday, K. (LEO Pharma A/S) ;
Warren, R. B. (University of Manchester) ;
Universitat Autònoma de Barcelona
Brodalumab is a monoclonal antibody that blocks multiple interleukin (IL)-17 family cytokines by binding to the shared A subunit of the IL-17 receptor. In Phase 3 trials, brodalumab provided high levels of skin clearance through 52 weeks in patients with moderate-to-severe psoriasis and was generally well tolerated. [...]
2022 - 10.1111/jdv.18068
Journal of the European Academy of Dermatology and Venereology, Vol. 36 Núm. 8 (august 2022) , p. 1275-1283
|
|
|
17.
|
|
10 p, 1.8 MB |
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
/
Reich, Kristian (University Medical Center Hamburg-Eppendorf) ;
Conrad, Curdin (University Hospital Lausanne CHUV) ;
Kristensen, Lars Erik (Lund University) ;
Smith, Saxon D. (The University of Sydney) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Rich, Phoebe (Oregon Dermatology and Research Center) ;
Sapin, Christophe (Eli Lilly and Company) ;
Holzkaemper, Thorsten (Eli Lilly and Company) ;
Koppelhus, Uffe (Eli Lilly and Company) ;
Schuster, Christopher (Medical University of Vienna) ;
Universitat Autònoma de Barcelona
Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics. [...]
2022 - 10.1080/09546634.2021.1892024
Journal of Dermatological Treatment, Vol. 33 Núm. 3 (2022) , p. 1652-1660
|
|
|
18.
|
|
7 p, 914.8 KB |
Development and Preliminary Validation of the HSQoL-24 Tool to Assess Quality of Life in Patients With Hidradenitis Suppurativa Desarrollo y validación preliminar del instrumento HSQoL-24 para evaluar calidad de vida en pacientes con hidradenitis supurativa
/
Marrón, Servando E. (Grupo Español de Investigación en Dermatología y Psiquiatría (GEDEPSI) de la Academia Española de Dermatología y Venereología (AEDV)) ;
Gómez-Barrera, Manuel (Universidad San Jorge) ;
Tomás-Aragonés, Lucía (Grupo Español de Investigación en Dermatología y Psiquiatría (GEDEPSI) de la Academia Española de Dermatología y Venereología (AEDV)) ;
Díaz Díaz, Rosa María (Grupo Español de Investigación en Dermatología y Psiquiatría (GEDEPSI) de la Academia Española de Dermatología y Venereología (AEDV)) ;
Vilarrasa Rull, Eva (Institut d'Investigació Biomèdica Sant Pau) ;
Madrid Álvarez, María Blanca (Grupo Español de Investigación en Dermatología y Psiquiatría (GEDEPSI) de la Academia Española de Dermatología y Venereología (AEDV)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the skin with a negative impact on quality of life. Up to now, there are no disease specific instruments in Spanish to assess quality of life in HS. [...]
2019 - 10.1016/j.ad.2019.02.002
Actas Dermo-Sifiliograficas, Vol. 110 Núm. 7 (septiembre 2019) , p. 554-560
|
|
|
19.
|
|
15 p, 804.8 KB |
Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies
/
Sánchez-Rodríguez, Guillermo (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomedica Sant Pau) ;
Universitat Autònoma de Barcelona
The interleukin 17 (IL-17) family, a subset of cytokines consisting of IL-17A-F, plays crucial roles in host defence against microbial organisms and the development of inflammatory diseases, including psoriasis (PsO), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). [...]
2023 - 10.3390/ijms241210305
International journal of molecular sciences, Vol. 24 (june 2023)
|
|
|
20.
|
|
14 p, 695.4 KB |
Comparative effectiveness of biologics in clinical practice : week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)
/
Pinter, Andreas (University Hospital of Frankfurt (Alemanya)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Schäkel, Knut (Heidelberg University Hospital (Alemanya)) ;
Reich, Adam (Institute of Medical Sciences. Medical College of Rzeszow University) ;
Zaheri, Shirin (Imperial College Healthcare NHS Trust) ;
Costanzo, Antonio (Humanitas Research Hospital Pieve Emanuele (Milà, Itàlia)) ;
Tsai, Tsen-Fang (National Taiwan University Hospital and National Taiwan University College of Medicine) ;
Smith, Saxon Donald (Australian National University,College of Health and Medicine) ;
Lynde, Charles W. (University of Toronto) ;
Brnabic, Alan (Eli Lilly and Company) ;
Reed, Catherine L. (Eli Lilly and Company) ;
Hill, Julie (Eli Lilly and Company) ;
Schuster, Christopher F. (Medical University of Vienna) ;
Riedl, Elisabeth (Medical University of Vienna) ;
Paul, Carle (Paul Sabatier University and Larrey Hospital (Toulose, França)) ;
Universitat Autònoma de Barcelona
Background: Clinical trials study treatment outcomes under stringent conditions, capturing incompletely the heterogeneity of patient populations and treatment complexities encountered in real-world practice. [...]
2022 - 10.1111/jdv.18376
Journal of the European Academy of Dermatology and Venereology, Vol. 36 Núm. 11 (november 2022) , p. 2087-2100
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
